These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19502180)

  • 1. Chemo brain, antiestrogens, and me.
    Simmons CC
    Clin J Oncol Nurs; 2009 Jun; 13(3):253-4. PubMed ID: 19502180
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiestrogens: the past and the future.
    Bentrem DJ; Jordan VC
    Zentralbl Gynakol; 2002 Dec; 124(12):551-8. PubMed ID: 12822068
    [No Abstract]   [Full Text] [Related]  

  • 3. [Should chemotherapy or endocrine therapy be used as first choice in patients with advanced breast cancer? A status article based on the Cochrane analysis "Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer"].
    Ejlertsen B; Mouridsen H
    Ugeskr Laeger; 2004 Jun; 166(25):2434-6. PubMed ID: 15283108
    [No Abstract]   [Full Text] [Related]  

  • 4. Cognitive decline in breast cancer patients.
    Health News; 2004 Nov; 10(11):9. PubMed ID: 15655856
    [No Abstract]   [Full Text] [Related]  

  • 5. Lost in the fog: understanding "chemo brain".
    Hafner DL
    Nursing; 2009 Aug; 39(8):42-5. PubMed ID: 19633502
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant chemotherapy and cognitive dysfunction in breast cancer patients.
    J Support Oncol; 2006 Feb; 4(2):66-7. PubMed ID: 16499119
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update).
    Grunfeld E; Dhesy-Thind S; Levine M;
    CMAJ; 2005 May; 172(10):1319-20. PubMed ID: 15883407
    [No Abstract]   [Full Text] [Related]  

  • 8. The influence of priming and pre-existing knowledge of chemotherapy-associated cognitive complaints on the reporting of such complaints in breast cancer patients.
    Schagen SB; Das E; van Dam FS
    Psychooncology; 2009 Jun; 18(6):674-8. PubMed ID: 19021129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The safety of endocrine therapy in breast cancer].
    Li T; Hu XC
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(20):1376-8. PubMed ID: 22883192
    [No Abstract]   [Full Text] [Related]  

  • 10. Cognitive adverse effects of chemotherapy in breast cancer patients.
    Correa DD; Ahles TA
    Curr Opin Support Palliat Care; 2007 Apr; 1(1):57-62. PubMed ID: 18660726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy?
    Raffa RB; Duong PV; Finney J; Garber DA; Lam LM; Mathew SS; Patel NN; Plaskett KC; Shah M; Jen Weng HF
    J Clin Pharm Ther; 2006 Apr; 31(2):129-38. PubMed ID: 16635046
    [No Abstract]   [Full Text] [Related]  

  • 12. The fog hasn't lifted on "chemobrain" yet: ongoing uncertainty regarding the effects of chemotherapy and breast cancer on cognition.
    Vardy J; Dhillon H
    Breast Cancer Res Treat; 2010 Aug; 123(1):35-7. PubMed ID: 20052534
    [No Abstract]   [Full Text] [Related]  

  • 13. The chemobrain controversy.
    Mettner J
    Minn Med; 2012 Jan; 95(1):12-3. PubMed ID: 22355903
    [No Abstract]   [Full Text] [Related]  

  • 14. Skipping chemo. A lot of breast-cancer survivors are doing it, not always for good reasons.
    Gupta S
    Time; 2003 Feb; 161(5):68. PubMed ID: 12608103
    [No Abstract]   [Full Text] [Related]  

  • 15. Cognitive function in breast cancer survivors.
    Vardy J
    Cancer Treat Res; 2009; 151():387-419. PubMed ID: 19593525
    [No Abstract]   [Full Text] [Related]  

  • 16. New research sheds light on "chemobrain".
    Harv Womens Health Watch; 2007 Feb; 14(6):7. PubMed ID: 17330340
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemo brain - a psychotropic drug phenomenon?
    Jackson GE
    Med Hypotheses; 2008; 70(3):572-7. PubMed ID: 17686588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer treatment and cognitive functioning: current status and future challenges in assessment.
    Castellon SA; Silverman DH; Ganz PA
    Breast Cancer Res Treat; 2005 Aug; 92(3):199-206. PubMed ID: 16155790
    [No Abstract]   [Full Text] [Related]  

  • 19. How far have we come in terms of estrogens in breast cancer? [Review].
    McNamara KM; Guestini F; Sakurai M; Kikuchi K; Sasano H
    Endocr J; 2016 May; 63(5):413-24. PubMed ID: 27020038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer and "chemobrain": the consequences of cognitive difficulties following chemotherapy and the potential for recovery.
    Reid-Arndt SA
    Mo Med; 2009; 106(2):127-31. PubMed ID: 19397112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.